市場調查報告書
商品編碼
1442913
血管成形術球囊支架 - 全球市場回顧、競爭格局、市場預測 (2030)Angioplasty Balloons And Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
預計 2024 年至 2030 年預測期內,全球血管成形術球囊和支架市場規模將以 3.67% 的複合年增長率成長。對血管成形術球囊支架的需求主要是由於心血管疾病(CVD)患者數量的增加、對微創手術的需求不斷增加以及藥物塗層/藥物洗脫球囊的不斷創新所推動的。此外,由於該領域正在進行的大量研究活動以及醫療保健提供者、研究人員、行業參與者等之間的聯盟和戰略夥伴關係,血管成形術球囊支架市場預計將增長。預計將在預測期內為整體市場成長做出貢獻~2030。
血管成形術球囊支架的市場動態
根據American Heart Association(2022)的數據,2020年全球約有2.441億人患有冠狀動脈心臟病(缺血性心臟病)。
根據British Heart Foundation(2022)的數據,2019 年全球約有5.5 億人(每14 人中就有1 人)患有心臟和循環系統疾病,其中約2.9 億人包括1 萬名女性和約2.6 億男性。據同一消息來源稱,2019年,北美有4,103,135人被診斷出患有心血管疾病,1,089,947人被診斷出患有冠狀動脈疾病,498,551人被診斷出患有中風,亞洲有32,376,834人被診斷出患有心血管疾病,其中12,543,833人患有心血管疾病。冠狀動脈疾病和 8,111,044 人患有中風。
文件進一步指出,冠狀動脈心臟病、週邊動脈疾病、中風和心房顫動仍是2019年全球最常見且流行的心血管疾病。
越來越多的危險因子導致心血管疾病的發展,如肥胖、高血壓、糖尿病、吸菸、老年、飲酒、不健康的生活習慣和動脈粥狀硬化,這會進一步加速推動血管成形術球囊支架市場的發展。
根據世界衛生組織(2022)提供的數據,2020年,全球約有10億人年齡在60歲或以上。到2050年,60歲及以上的老年人口預計將增加一倍,達到約21億人。
研究表明,PAD 的盛行率隨著年齡的增長而增加,影響 60 歲以下人群的 3%,但 70 歲以上人口的盛行率則增至 15% 至 20%。
因此,由於上述因素,血管成形術球囊支架市場預計將在預測期內成長。
然而,嚴格的監管程序和產品召回造成的不利影響可能會抑制血管成形術球囊支架市場的整體成長。
血管成形術球囊和支架市場細分分析
在血管成形術球囊和支架市場的球囊類別的產品類型部分,藥物塗層球囊預計將在 2023 年佔重要的收入佔有率。
藥物塗層球囊在治療冠狀動脈疾病和周邊動脈疾病的益處和應用預計將增加其需求。
藥物塗層球囊(DCB)血管成形術在程序上與傳統球囊血管成形術(POAB)相同,但球囊上塗有抗增殖藥物和賦形劑以增強藥物輸送。
藥物塗層球囊有助於預防再狹窄。使用藥物塗層球囊可以抑制細胞分裂並減少治療後再狹窄或閉塞再生的程度。
DCB血管成形術中不會植入異物,患者的身體不僅不會改變冠狀動脈原有的解剖結構,也不會產生晚期支架血栓和過敏等風險。
此外,它還提供了進一步手術和介入治療的可能性,特別是對於年輕患者。
本報告提供了全球血管成形球囊和支架市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
The Angioplasty Balloons And Stents Market By Product Type (Balloons [Drug-Coated Balloons And Plain Old Balloons], Stents [Drug-Eluting Stents And Bare Metal Stents]), Indication (Coronary Artery Disease And Peripheral Artery Disease), End-User (Hospitals, Ambulatory Surgical Centers, And Cath Labs), and geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing number of cases of urinary tract infections (UTI) and increasing research and development activities
The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030. The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.
Angioplasty Balloons And Stents Market Dynamics:
According to American Heart Association 2022 data, globally about 244.1 million people were living with coronary (ischemic) heart disease in 2020.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men. As per the same source, in 2019, in North America, cardiovascular diseases affected 4,103,135 people, 1,089,947 people were diagnosed with coronary artery disease, and 498,551 suffered from stroke; In Asia, there were 32,376,834 people diagnosed with cardiovascular diseases, from which 12,543,833 individuals were affected by coronary artery disease, and 8,111,044 population was suffered from a stroke.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
The increasing number of risk factors such as obesity, hypertension, diabetes, smoking, old age, alcohol consumption, unhealthy lifestyle, atherosclerosis, and others causing the development of cardiovascular diseases in one way or another are further going to accelerate the market for angioplasty balloons and stents.
According to the data provided by the WHO (2022), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people.
As per research studies, the prevalence of PAD increases with age; it occurs in 3% of people <60 years, but its prevalence increases to 15% to 20% among individuals >70 years.
Thus, owing to the above-mentioned factors, the angioplasty balloons and stents market is estimated to grow during the forecast period.
However, stringent regulatory procedures adverse effects, and product recalls may restrict the growth of the overall angioplasty balloons and stents market.
Angioplasty Balloons And Stents Market Segment Analysis:
Angioplasty Balloons and Stents Market By Product Type (Balloons [Drug-Coated Balloons and Plain Old Balloons], Stents [Drug-Eluting Stents and Bare Metal Stents]), Indication (Coronary Artery Disease and Peripheral Artery Disease), End-User (Hospitals, Ambulatory Surgical Centers, and Cath Labs), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment under the balloons category of the Angioplasty Balloons and Stents market, the drug-coated balloons, category is expected to amass a significant revenue share in the year 2023.
The advantages and applications associated with drug-coated balloons in the treatment of coronary artery disease and peripheral artery disease are going to increase their demand.
Procedure-wise, Drug-Coated Balloon (DCB) angioplasty is comparable to Plain Old Balloon Angioplasty (POAB), but it includes coating the balloon with an anti-proliferative medicine and an excipient to facilitate drug transfer.
Drug-coated balloons aid in the prevention of restenosis, which is the vessel's re-narrowing at a previously treated spot. Employing a balloon coated with medication may prevent cell division, thereby reducing the degree of restenosis, or blockage regrowth, following therapy.
By not implanting a foreign body during the DCB angioplasty, the patient's body is spared from modifications to the coronary artery's original anatomical structure as well as risks such as late stent thrombosis and allergy.
Additionally, it offers chances for further surgical treatment or interventional therapy, especially for young patients.
The interventional process is comparatively easy, requiring less time to complete and exposing patients and medical personnel to less radiation.
By uniformly distributing the medication to the blood vessel's inner wall, DCB can prevent the delayed endothelialization brought on by the unequal dispersion of stent metal rods.
By applying DCB, the duration of dual antiplatelet medication can be shortened, and the risk of bleeding and other problems can be decreased.
For certain kinds of lesions, such as narrow lesions, high bleeding risk lesions, patients with diabetes, etc., DCB may be a better option than stent insertion.
Thus, all the above-mentioned factors are likely to propel the market for drug-coated balloons in Angioplasty Balloons and Stents.
North America is expected to dominate the overall Angioplasty Balloons And Stents Market:
Among all the regions, North America is estimated to account for the largest share of the Angioplasty Balloons and Stents market in the year 2023. This domination is due to the increasing application of angioplasty balloons and stents in the treatment and management of peripheral and coronary artery disease which are on the rise in the region, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases, rising product launch and approvals, presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.
For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) in 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have coronary artery disease (CAD). Coronary heart disease is the most common type of heart disease in the US, killing 375,476 people in 2021. In 2021, about 2 in 10 deaths from CAD happened in adults less than 65 years old. Thus, the high burden of cardiovascular diseases in the region demands the availability of drug-eluting balloons.
The American Heart Association in the latest study estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are carried out annually in the US. Percutaneous coronary intervention with a drug-coated balloon (DCB) is a novel treatment that seeks to acutely dilate coronary stenosis and deliver an anti-proliferative drug to the vessel wall. Thus, the number of PCI procedures in the region will increase the demand for drug-eluting balloons.
Further, the availability of various major manufacturers, the launch and approval of new and technologically advanced devices, and favorable reimbursement regulations are all important factors responsible for driving the demand for drug-eluting balloons in the region. For instance, in November 2022, Genesis MedTech Group announced that the Food and Drug Administration (FDA) has approved the Chocolate Touch(R) Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
Thus, the above-mentioned factors are likely to propel the growth of the angioplasty balloons and stents market in the region during the forecast period from 2024-2030.
Angioplasty Balloons And Stents Market Key Players:
Some of the key market players operating in the Angioplasty Balloons and Stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.
Recent Developmental Activities in the Angioplasty Balloons And Stents Market:
Key Takeaways from the Angioplasty Balloons And Stents Market Report Study
Target Audience who can be benefited from this Angioplasty Balloons And Stents Market Report Study
Frequently Asked Questions for the Angioplasty Balloons And Stents Market:
Angioplasty Balloons and Stents are intended for the effective treatment of coronary and peripheral artery disease by opening a narrowed or blocked artery.
The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030.
The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.
Some of the key market players operating in the angioplasty balloons and stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.
North America is expected to dominate the overall Angioplasty Balloons and Stents market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing patient pool with peripheral and coronary artery disease, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases. Further, rising product launches and approvals and, the presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.